# KDIGO 2026 kidney disease and heart failure conference report processing report

## Activated macros

- `@ATOM`
- `@SEA`

## Source

- Title: *Kidney Disease and Heart Failure: Recent Advances and Current Challenges*
- Subtitle: *Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference*
- Journal: *JACC: Heart Failure*
- Year: 2026
- Volume: 14
- Issue: 4
- Article: 102943
- DOI: `10.1016/j.jchf.2026.102943`
- Conference date: March 2024
- Source type: KDIGO Controversies Conference executive conclusions and secondary evidence synthesis
- PDF pages: 21
- SHA-256: `0dfefe13c45f5caecff5adfdb81e7375a33f9f27196441edca857da582d042fc`
- Shared publication ID: `0cea780d-199b-5f90-a9b6-aa10a34a7425`

## ATOM result

Total LiteratureAtoms: **81**

| Atom kind | Count |
|---|---:|
| `author_conclusion` | 34 |
| `conflict_of_interest` | 1 |
| `funding_disclosure` | 1 |
| `limitation` | 13 |
| `method` | 2 |
| `other` | 29 |
| `study_objective` | 1 |

Batch plan:

| Batch | Pages | Scope |
|---|---|---|
| `kdigo-2026-hf-ckd-global-v1` | 1-2, 17-18 | source identity, purpose, conference method, global conclusions, disclosures |
| `kdigo-2026-hf-ckd-pathophysiology-v1` | 2-6 | pathophysiology, hemodynamics, tubular health, common-soil model |
| `kdigo-2026-hf-ckd-diagnosis-v1` | 5-9 | kidney assessment in HF, AKI/creatinine dilemmas, natriuretic peptides, imaging, volume attribution, HF staging |
| `kdigo-2026-hf-ckd-treatment-v1` | 9-14 | HFrEF/HFpEF therapy, kidney-function changes with GDMT, iron, lifestyle, decongestion, diuretic and ultrafiltration frameworks |
| `kdigo-2026-hf-ckd-trials-v1` | 4-5, 14-17 | Table 1 research agenda, trial inclusion, biomarkers, endpoints, PROMs, core data sets, future research |
| `kdigo-2026-hf-ckd-conclusions-v1` | 17-18 | whole-source conclusions, conflicts, funding |

Validation status:

- Local reconstructed Pydantic contract: **PASS**
- Local reconstructed JSON Schema validation: **PASS**
- Sufficiency checks for extracted atom kinds: **PASS**
- Structural errors: **0**
- JSON Schema errors: **0**
- Sufficiency errors: **0**
- Sufficiency warnings: **0**
- Duplicate atom IDs: **0**
- Exact duplicate canonical statements: **0**

Validation boundary: the authoritative project files `literature.py`, `literature_atoms.py`, `literature_atom.schema.json`, `README(2).md`, and `example_atom.json` were not directly retrievable in this runtime. Validation used a strict local contract reconstructed from recent validated project artifacts and the large-source ATOM+SEA guardrail. This report does not claim that the authoritative project validation code ran.

Source-type boundary: this publication is a consensus conference report. Results from cited trials and observational studies remain secondary evidence summaries. They were not represented as if KDIGO enrolled those participants or generated those results.

## SEA result

The SEA artifact is a self-contained HTML appraisal. Final scoring was performed after source mapping, ATOM extraction, and figure/table reconciliation.

Appraisal scores:

- Relevance: **10/10**
- Novelty: **8/10**
- Method strength: **6/10**
- Evidence strength: **7/10**
- External validity: **7/10**
- Implementation value: **9/10**

The report is most useful for interpreting kidney-function changes during HF treatment, integrating eGFR and UACR into cardiorenal assessment, contextualizing natriuretic peptides in CKD, guiding decongestion monitoring, and defining research priorities. It is not a graded KDIGO clinical practice guideline.

## Figure and table reconciliation

| Object | Page | Status |
|---|---:|---|
| Figure 1, placebo HF and CKD event burden across trial programs | 3 | Represented |
| Table 1, knowledge gaps and research strategies | 4-5 | Represented |
| Figure 2, HF-CKD pathophysiology | 6 | Represented |
| Figure 3, HF staging with CKD | 8 | Represented |
| Table 2, therapy thresholds and adverse-effect management | 10 | Represented |
| Figure 4, medical management by eGFR | 11 | Represented |
| Figure 5, acute diuretic framework | 13 | Represented |
| Figure 6, trial populations and outcomes | 14 | Represented |

All six figures and both tables were reconciled. No main-text visual was silently omitted.

## Reference extraction

- Reference pages: 18-21
- Numbered references extracted: **132**
- Sequence check: **1 through 132 complete**
- Bibliography atomized: **No**
- Output format: Markdown

## SEA mechanical QA

- HTML exists: **True**
- Byte size: **31399**
- Title present: **True**
- DOI present: **True**
- Navigation anchors resolve: **True**
- Missing anchors: **[]**
- Internal chat/file citation syntax absent: **True**
- Unfinished markers absent: **True**
- Placeholder markers absent: **True**
- Main figure/table objects represented: **8 of 8**

## Extraction limitations

- The conference report is a secondary source and does not replace reading cited primary studies when primary-study evidence is needed.
- Advanced CKD, dialysis-treated kidney failure, and stage D HF are repeatedly identified by the report as evidence gaps.
- The report does not describe a systematic review, formal GRADE process, or reproducible voting method for each consensus statement.
- The named `summary-evaluation-appraisal-protocol-v4-compact.md` file was not directly retrievable in this runtime. The large-source ATOM+SEA skill and recent validated project SEA conventions were applied.
- No external literature verification was added because the request was to process the supplied source.

## Output files

- `KDIGO-2026-Kidney-Disease-and-Heart-Failure-Conference-Report-atoms.json`
- `KDIGO-2026-Kidney-Disease-and-Heart-Failure-Conference-Report-validation.json`
- `KDIGO-2026-Kidney-Disease-and-Heart-Failure-Conference-Report-sea.html`
- `KDIGO-2026-Kidney-Disease-and-Heart-Failure-Conference-Report-references.md`
- `KDIGO-2026-Kidney-Disease-and-Heart-Failure-Conference-Report-processing-report.md`
